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Abstract
Long term storage of the anti-doping samples and their 
 reanalyses becomes today more and more a trend in the an-
ti-doping community. The procedure has been implemented 
by the anti-doping authorities for the samples of the Tour de 
France and for the Olympic Games since Athens 2004 and 
has been always presented as a good tool to deter doping 
habits in top level sport. 
Recently, the World Anti-Doping Code introduced the 
possibility for anti-doping organizations to store the athletes’ 
samples up to ten years. The anti-doping authorities may ask 
to reanalyze the samples at any time during that period of 
time as a function of the implementation of new methods or 
instruments in the accredited laboratories allowing the de-
tection of prohibited substances or their metabolites at a 
much lower concentration or for a larger detection window. 
The most significant technological advances for the detection 
of doping substances have been done in the characterization 
of various long-term metabolites of anabolic androgenic ster-
oids. This allowed for increasing the time of detection by 
even a factor of four. 
Keywords: 
sport, World Anti-Doping Agency (WADA), anabolic andro-
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Résumé
Le stockage à long terme des échantillons anti-dopage, ainsi 
que leurs ré-analyses sont de plus en plus prisé par la com-
munauté anti-dopage. Cette procédure de conservation des 
échantillons avait d’abord été mise en place par les autorités 
anti-dopage pour le Tour de France, puis pour les Jeux Olym-
piques depuis ceux d’Athènes en 2004. Ceci a toujours été 
présenté comme bon outil de dissuasion pour lutter contre les 
habitudes de dopage dans le sport de haut niveau. 
Récemment, le Code Mondial Antidopage a introduit la 
possibilité pour les organisations antidopage de conserver les 
échantillons des athlètes jusqu’à dix ans.
Ainsi, ces organisations peuvent demander à tout moment 
pendant cette période de ré-analyser les échantillons conser-
vés, en fonction de l’introduction de nouvelles méthodes 
d’analyse ou de nouveaux instruments dans les laboratoires 
antidopage. Ceci doit permettre de détecter les substances 
interdites (ou leurs métabolites) à des concentrations plus 
basses, augmentant de ce fait leur fenêtre de détection. Ré-
cemment, les avances technologiques les plus significatives 
ont été faites dans la caractérisation des plusieurs métabolites 
à long terme de stéroïdes androgènes anabolisants. Ceci a 
permis d’augmenter par un facteur quatre le temps de détec-
tion de ces substances. 
Mots clés:
Sport, Agence Mondiale Anti-dopage (AMA), stéroïdes 
anabolisants androgènes, dopage, liste des produits interdits
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Introduction
Since the end of the nineties, all anti-doping urine samples 
collected during the Tour de France are stored for long term 
by the French anti-doping authorities. The urine samples 
from Tour de France 1999 were reanalyzed in 2005 for the 
detection of EPO and in several cases synthetic EPO was 
detected. This new method, invented by the Châtenay Mal-
abry Laboratory [1] has been officially implemented for the 
first time during the Sydney Olympic Games in 2000. At the 
time, this example was one of the most spectacular applica-
tions of the principle of long term storage and reanalysis with 
a new or improved technology. 
In 2004, the recommendation of the new World Anti-dop-
ing Code (2003) was implemented in the anti-doping rules 
of the International Olympic Committee (IOC) and for the 
Athens Olympic Games all the anti-doping samples were 
stored frozen for long term up to eight years.
At the level of the Olympic Games, the first operation of 
reanalyses was done in 2009, six months after the 2008 Bei-
jing Games. A new method for the detection of C.E.R.A. 
(Continuous Erythropoetin Receptor Activator, third gener-
ation EPO) was implemented soon after the Games by two 
laboratories [2,3] and they were requested to reanalyze all 
the serum samples collected during the Games. As the out-
come of this operation of retesting, seven cases (correspond-
ing to six athletes) were found positive for C.E.R.A. 
In 2012, the IOC ordered several reanalyses concerning 
the 2004 Athens samples, due to significant improvements in 
the analytical methods which were implemented within this 
timeframe in the laboratories accredited by the World An-
ti-Doping Agency (WADA). The new methods allowed for 
dramatic extension of the detection time window of several 
prohibited substances and their representative metabolites. 
After these pioneering operations several retests have been 
done from other Olympic Games and major competitions.
World anti-doping code and international  
standards
The 2015 World Anti-Doping Code allows for the storage 
of samples for up to 10 years, which markedly transforms 
the anti-doping environment as the retesting with newly 
designed analytical methods is considered as very impor-
tant and powerful tool for the deterrence effect [4]. The new 
2015 International Standard on Testing and Investigations 
[5] sets out the requirements for anti-doping organizations 
(ADOs) to test, store and reanalyze samples. The responsi-
bility for setting the priorities and selection of samples for 
the long-term storage is the responsibility of the ADOs, e.g. 
international federations (IFs) and national anti-doping 
agencies (NADOs), and based on their risk assessment. For 
the success of retesting, it is important that the storage of 
samples is conducted in a manner that enables application 
of future methods that may not yet be fully developed or 
operational.
These conditions are extensively described by the Inter-
national Standard for Laboratories [6] (ISL, 2015, # 5.2.2.12 
Long term storage of samples) and the duties of testing au-
thorities and laboratories can be summarized as follows: 
– Any sample may be stored in long-term storage for up to 
ten years. 
– The testing authority should retain the official doping con-
trol records for the duration of sample storage.
– The laboratory should retain all chain of custody docu-
ments for the duration of sample storage.
– If samples are to be stored at a location outside the secured 
area of the laboratory which first analyzed the sample, the 
laboratory shall secure the A- samples to be shipped in a 
manner which ensures integrity and chain of custody of 
the sample. 
– During transport and long-term storage, samples shall be 
maintained at a temperature sufficient to maintain the an-
alytical integrity of the sample.
– The long-term storage facility shall maintain security re-
quirements comparable to the security requirements appli-
cable to short-term storage facilities in the laboratory. 
– Samples held in long-term storage may be selected for 
 reanalysis at the discretion of the testing authority or 
WADA. 
– Further analysis on long-term stored samples shall proceed 
by taking all necessary precautions in order to preserve 
the quality of the analyses and the rights of the athlete. If 
the full initial testing and confirmation procedure is not 
completed on the A-sample, the testing authority shall ap-
point an independent witness to verify the opening and 
splitting of the sealed B-sample and then proceed to anal-
ysis based on the B-sample which has been split into 2 
bottles.
Long term storage conditions and costs
Logistics and maintenance of the long-term storage requires 
laboratory resources, and depending on the number of sam-
ples and the time period, the costs can be significant and 
exponential. Among the ADOs and event organizers the op-
erational environment may vary greatly and especially with 
limited budgets it is necessary to build up a strategy in order 
to keep only the prioritized samples and to control the costs 
of long-term storage. These strategies must certainly be 
based on intelligence, which is derived from non-analytical 
and analytical information accompanied by specific risk as-
sessment. 
What to retest and when?
Even if the ADOs have been given the right to retest the 
samples up to 10 years after the collection, it is not necessar-
ily the best option to wait with the analysis until the very end 
of that period. 
Whichever will the timeline be, the key element of retest-
ing is certainly the capability to apply new methodologies or 
to take the advantage of significant improvements in the de-
tection methods.
In general, the improvements are due to major technical 
steps in the instrument development, which may either enable 
discovery of new types of target compounds or increase the 
sensitivity and the specificity of the detection. As a result of 
these advances new metabolites can be discovered and also 
the detection time window of traditional metabolites can be 
dramatically increased. 
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The cases of AAS
The first significant advance in the long-term detection has 
been reached with anabolic androgenic steroids (AAS), 
which are among the most frequently detected drugs in am-
ateur and professional sports. One of the first steps in that 
direction was done in Cologne [7] with respect to pharma-
cokinetics and excretion profiles of metandienone and its 
metabolites. A new metandienone metabolite (18-nor-17beta-
hydroxymethyl,17alpha-methyl-androst-1,4,13- trien-3- one) 
was identified by the Cologne team in excretion study urine 
samples. This new metabolite was characterized using gas 
chromatography/(tandem) mass spectrometry, liquid chroma-
tography/tandem mass spectrometry and liquid chromatog-
raphy/high-resolution/high-accuracy (tandem) mass spec-
trometry. 
The 18-Nor-17beta-hydroxymethyl,17alpha-methyl-an-
drost-1,4,13-trien-3-one was determined in metandienone 
administration study urine specimens up to 19 days after 
application of a single dose of 5 mg, hence providing an ex-
tended detection period compared with commonly employed 
strategies. This observation provided a valuable tool for the 
long-term detection of metandienone abuse by athletes in 
sports drug testing and resulted in an increase of adverse 
analytical findings (AAFs) of metandienone for more than 
400% from approximately 12-15 AAFs in the years 2003-
2005 to 68 AAFs in 2006, although the number and origin 
of the analyzed samples was nearly constant [8]. 
The same group of researchers applied similar strategies 
by using the benefits of instrument development to improve 
the detection of other steroids, apparently widely used by 
top-level athletes. The group was able to enhance the analyt-
ical possibilities to detect stanozolol misuse by the detection 
of stanozolol glucuronides [9] and of oxandrolone [10]. 
Another step forward in the detection of a widely used 
steroid, dehydrochloro-methyltestosterone (“Oral-Turina-
bol”), was taken by Russian laboratory [11] for the detection 
and the characterization of novel urinary long-term metabo-
lites and the results of their study have extended the detection 
time of this particular substance in a significant manner. Ac-
cording to a practical example provided by the laboratory, 
inclusion of the novel metabolite to the routine analysis re-
sulted in 15 adverse analytical finding whereas only five of 
the cases could have been detected by monitoring only two 
more traditional metabolites. 
Result management
There are several important issues related to the reporting 
from the laboratory and for the result management by the 
anti-doping organization. 
Which list of prohibited substances is applicable?
The date of sample collection defines the list of prohibited 
substances for the reanalysis. Consequently, e.g. the reanal-
yses performed on the samples from the IAAF World Cham-
pionships held in 2007 in Osaka (JPN) are based on the 2007 
WADA list of prohibited substances. Nevertheless, it is im-
portant to know that for the most categories of substances the 
list is constructed as open, i.e. any other substances with a 
similar chemical structure or similar biological effect(s) will 
be analogously recognized as prohibited. For example, in the 
prohibited list 2007, many substances are cited as examples 
in the category “S1.1.a Exogenous Anabolic Androgenic 
Steroids”. This means that any new designer steroid which 
was used in 2007 without being detectable by the anti-doping 
laboratory at the time of the competition could be potential-
ly reported as an AAF if detected in the stored samples when 
analyzed less than 8 years after. 
What is the ideal timeframe for the reanalyses?
Several points must be taken into consideration when the 
decision is made for an ideal timeframe for the retesting. The 
entire technical process is time-consuming: starting from the 
administrative work of locating the samples among different 
laboratories, and ending with B-split or B-sample analysis 
with the obligation to preserve the rights of the athlete. The 
rules define the possibility for the athlete to witness the 
B-split or the B-analysis. Eight or ten years after a major 
competition, it may be difficult to reach the athlete or to mo-
tivate participation in such a procedure. Consequently, there 
will be a question of a reasonable effort by the anti-doping 
organization to reach the athlete and it is certainly a legal 
issue, which must be better defined in the future to improve 
the flow of the procedure. For example, should it be neces-
sary, or even possible, to keep in a specific database all the 
whereabouts information of the athletes who have already 
retired from active career or who are otherwise difficult to 
reach? 
Communication and deterrence effect
The timeline defined for the retesting and the quality of the 
communication of the results are the two key issues to obtain 
the best deterrence effect of any operations of reanalyses. 
On one hand, it is obviously necessary to wait for a certain 
period of time to allow the laboratories to develop new or 
more sensitive detection methods. But on the other hand, if 
the retest is performed very long time after the initial com-
petition dates (10 years is quite long in the sport’s perspec-
tive), the audience could be a completely new generation of 
athletes and the deterrence effect could be decayed. 
There is always also the question if the negative reanaly-
sis results could not definitively validate the results of those 
athletes eight or ten years after the competition. Whichever 
a percentage of adverse analytical findings is returned from 
the reanalysis process (e.g. 10%), a high number of samples 
will be then declared negative (in our case 90%). The out-
come could be also supportive to these athletes who could 
validate their results or medal.
Conclusion & perspectives
There are many factors to take into account for the strategy 
and execution of reanalyses. To our opinion, in order to reach 
a successful outcome, it is necessary to establish a dialog 
between all the operators. Representatives of the anti-doping 
organizations, athlete community, anti-doping laboratories 
and disciplinary panels must have regular contact to define 
the best strategies in specific context. In the fight against 
doping, it is accepted to harmonize the rules for the integrity 
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and equity in sport and to protect the clean athletes. How ever, 
it must be also acknowledged that the tools used for the im-
plementation of these principles must evolve quickly in a pro-
active manner and the reanalyses of long term stored samples 
must be seen in this perspective.
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